Skip to main content
Top
Literature
1.
go back to reference Swedlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon Swedlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon
2.
go back to reference Robbins BA, Ellison DJ, Spinosa JC et al (1993) Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277–1287PubMed Robbins BA, Ellison DJ, Spinosa JC et al (1993) Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 82:1277–1287PubMed
3.
go back to reference Juliusson G, Lenkei R, Liliemark J (1994) Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 83:3672–3681PubMed Juliusson G, Lenkei R, Liliemark J (1994) Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 83:3672–3681PubMed
4.
go back to reference Wu ML, Kwaan HC, Goolsby CL (2000) Atypical hairy cell leukemia. Arch Pathol Lab Med 124:1710–1713PubMed Wu ML, Kwaan HC, Goolsby CL (2000) Atypical hairy cell leukemia. Arch Pathol Lab Med 124:1710–1713PubMed
5.
go back to reference Jasionowski TM, Hartung L, Greenwood JH et al (2003) Analysis of CD10+ hairy cell leukemia. Am J Clin Pathol 120:228–235CrossRefPubMed Jasionowski TM, Hartung L, Greenwood JH et al (2003) Analysis of CD10+ hairy cell leukemia. Am J Clin Pathol 120:228–235CrossRefPubMed
6.
go back to reference Foon KA, Billing RJ, Terasaki PI (1980) Dual B and T markers in acute and chronic lymphocytic leukemia. Blood 55:16–20PubMed Foon KA, Billing RJ, Terasaki PI (1980) Dual B and T markers in acute and chronic lymphocytic leukemia. Blood 55:16–20PubMed
7.
go back to reference Chen YH, Tallman MS, Goolsby C, Peterson L (2006) Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol 125:251–259CrossRefPubMed Chen YH, Tallman MS, Goolsby C, Peterson L (2006) Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol 125:251–259CrossRefPubMed
8.
go back to reference Shao H et al (2013) Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 37:401–409CrossRefPubMed Shao H et al (2013) Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 37:401–409CrossRefPubMed
9.
go back to reference Sausville JE et al (2003) Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 119:213–217CrossRefPubMed Sausville JE et al (2003) Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 119:213–217CrossRefPubMed
Metadata
Title
Immunophenotypic Aberrancy of a Case of Hairy Cell Leukemia
Authors
Abhishek Purohit
S. Venkatesan
Mukul Aggarwal
Jasdeep Singh
Rahul Sharma
Manoranjan Mahapatra
Hara P. Pati
Renu Saxena
Publication date
01-06-2015
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2015
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0433-x

Other articles of this Issue 2/2015

Indian Journal of Hematology and Blood Transfusion 2/2015 Go to the issue

Editorial

Editorial

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine